Health-Med Archives - Page 13 of 50 - Yokohama City University

2023-03-02

Tax-related Incentives and Expense Allocation in Nonprofit Organizations: Evidence from Japan.

The research problem This study investigates the relationship between the incentive of Japanese non-profit organizations to avoid losing their tax-exempt status and the extent of tax-motivated expense allocation.

2023-02-27

Prevalence and clinical features of long COVID from omicron infection in children and adults.

We read with interest the article reported by Elda Righi et al. about persistent symptoms after COVID-19.1 Following acute infection, various long-lasting symptoms such as fatigue, headache, cough, and muscle pain are described as “long COVID.”2 The World Health Organization (WHO) and the United States Centers for Disease Control and Prevention (CDC) have given incongruous definitions.3, 4 The prevalence of long COVID varies widely, partly because of variability in definitions, study design, sampling frame, vaccine status, comorbidity, and other factors.

2023-02-21

Unique Mechanical Properties of Gel-Incorporating Protein Crystals

Crystalline materials that are grown in gel media exhibit reinforced mechanical characteristics. Studies on the mechanical properties of protein crystals are limited in numbers because of the difficulty in growing high-quality large crystals. This study shows the demonstration of the unique macroscopic mechanical properties by compression tests of large protein crystals grown in both solution and agarose gel.

2023-02-17

Intratracheal trimerized nanobody cocktail administration suppresses weight loss and prolongs survival of SARS-CoV-2 infected mice

Background SARS-CoV-2 Omicron variants are highly resistant to vaccine-induced immunity and human monoclonal antibodies. Methods We previously reported that two nanobodies, P17 and P86, potently neutralize SARS-CoV-2 VOCs. In this study, we modified these nanobodies into trimers, called TP17 and TP86 and tested their neutralization activities against Omicron BA.1 and subvariant BA.2 using pseudovirus assays. Next, we used TP17 and TP86 nanobody cocktail to treat ACE2 transgenic mice infected with lethal dose of SARS-CoV-2 strains, original, Delta and Omicron BA.1.